Eikon reports 63.1% response rate in Phase 2 EIK1001 first-line stage 4 NSCLC trial

Eikon Therapeutics, Inc.

Eikon Therapeutics, Inc.

EIKN

0.00
  • Eikon Therapeutics outlined new clinical updates for EIK1001 in first-line stage 4 NSCLC, with results already presented at the 2026 ASCO meeting.
  • The study strengthened the development case, showing broad tumor shrinkage signals and sustained disease control, with tolerability consistent with standard treatment.
  • It also released updated Phase 1/2 findings for PARP1 inhibitor EIK1003, with results already presented at ASCO 2026.
  • EIK1003 showed continued single-agent activity, with early combination activity alongside weekly paclitaxel in heavily pretreated patients, without unexpected safety signals.
  • Upcoming readouts include studies advancing EIK1001 into later-stage trials, with additional ASCO abstracts signaling expansion into melanoma and confirmatory NSCLC programs.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eikon Therapeutics Inc. published the original content used to generate this news brief on May 30, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.